Am­gen los­es ap­peal in patent suit against Sanofi/Re­gen­eron’s Pralu­ent. It’s a bum­mer for Bris­tol My­ers Squibb and Mer­ck, too

In a co­da to a six-year le­gal fight on the PC­SK9 ter­rain, the US Fed­er­al Court of Ap­peals has ruled that Am­gen’s patent claims for PC­SK9 an­ti­bod­ies as a class are in­valid, hand­ing a win to Sanofi and Re­gen­eron.

The im­pli­ca­tions, though, may re­ver­ber­ate far be­yond Am­gen.

The Thou­sand Oaks, CA-based com­pa­ny, whose Repatha was ap­proved a month af­ter Pralu­ent in 2015, may take com­fort in the fact that its sales have con­sis­tent­ly eclipsed Sanofi or Re­gen­eron’s, al­though nei­ther has climbed any­where near the block­buster ex­pec­ta­tions de­vel­op­ers and an­a­lysts had.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.